Rhythm Pharmaceuticals, Inc. (RYTM) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$197M, a net margin of -103.6%; the best year in this period was 2016 with -$29M.
Over the twelve months to September 30, 2026, revenue was $281M and net income -$198M.
Free cash flow was -$117M in fiscal 2025 and positive in 0 of the 10 years shown.
The diluted share count rose 537% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $281M | $190M | $130M | $77M | $24M | $3M | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $248M | $170M | $117M | $68M | $22M | $3M | — | — | — | — | — |
| Operating income | -$187M | -$192M | -$266M | -$184M | -$179M | -$170M | -$137M | -$146M | -$78M | -$32M | -$26M |
| Net income | -$198M | -$197M | -$261M | -$185M | -$181M | -$70M | -$134M | -$141M | -$74M | -$34M | -$29M |
| EPS (diluted) | $-2.90 | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 | $-3.04 | $-3.86 | $-2.39 | $-2.83 | $-2.85 |
| R&D | $180M | $167M | $238M | $135M | $109M | $104M | $90M | $109M | $50M | $23M | $20M |
| Revenue growth | — | +45.8% | +68.1% | +227.6% | +649.5% | — | — | — | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$82M | -$116M | -$114M | -$136M | -$173M | -$146M | -$122M | -$123M | -$62M | -$29M | -$23M |
| Capital spending | -$1M | -$953000 | $0 | -$47000 | -$281000 | -$434000 | -$214000 | -$3M | -$722000 | -$133000 | -$1M |
| Free cash flow | -$83M | -$117M | -$114M | -$136M | -$174M | -$146M | -$122M | -$126M | -$63M | -$30M | -$24M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $93M | $67M | $40M | $33M | $20M | $21M | $17M | $12M | $6M | $2M | $1M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $389M | $321M | $276M | $333M | $295M | $173M | $292M | $50M | $34M | $7M |
| Debt | — | $112M | $114M | $107M | $2M | $3M | $3M | $4M | $4M | — | — |
| Equity | — | $139M | $22M | $170M | $264M | $284M | $167M | $281M | $246M | $145M | -$33M |
| Total assets | — | $480M | $392M | $333M | $382M | $330M | $187M | $309M | $260M | $152M | $12M |
| Shares (diluted) | 69M | 65M | 61M | 58M | 52M | 50M | 44M | 36M | 31M | 13M | 10M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 88.2% | 89.7% | 89.7% | 88.0% | 91.0% | 81.0% | — | — | — | — | — |
| Operating margin | -66.7% | -101.2% | -204.0% | -238.1% | -757.9% | -5391.9% | — | — | — | — | — |
| Net margin | -70.6% | -103.6% | -200.3% | -238.5% | -766.2% | -2207.1% | — | — | — | — | — |
| FCF margin | -29.6% | -61.5% | -87.5% | -175.9% | -734.9% | -4642.9% | — | — | — | — | — |
| ROIC | — | -60.4% | -154.8% | -52.5% | -53.2% | -46.9% | -63.6% | -40.5% | -24.8% | -17.7% | — |
| ROE | — | -141.3% | -1199.3% | -108.8% | -68.5% | -24.5% | -80.5% | -50.1% | -30.1% | -23.3% | 88.9% |
Frequently asked questions
What is Rhythm Pharmaceuticals’s annual revenue?
$190M in fiscal 2025 and $281M over the twelve months to September 30, 2026.
How much profit does Rhythm Pharmaceuticals make?
Net income was -$197M in fiscal 2025 (net margin -103.6%).
Is Rhythm Pharmaceuticals’s revenue growing?
Yes: revenue rose 45.8% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.